# Power Integrations Inc: financial statements, quarterly

POWI · Nasdaq · CIK 833640 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/powi.md) · [Financials](/companies/powi/financials.md) · [Filings](/companies/powi/filings.md) · [Insiders](/companies/powi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/powi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [126](/filings/0000833640-24-000171.md) | [89.5 d](/filings/0000833640-26-000037.md) | [91.7](/filings/0000833640-25-000120.md) | [106](/filings/0000833640-25-000157.md) | [116](/filings/0000833640-25-000190.md) | [105 d](/filings/0000833640-26-000037.md) | [106](/filings/0000833640-26-000078.md) | [116](/filings/0000833640-26-000145.md) | [119](/filings/0000833640-25-000190.md) | [103 d](/filings/0000833640-26-000037.md) | [108](/filings/0000833640-26-000078.md) | [119](/filings/0000833640-26-000145.md) |
| Cost of revenue | $m | [59.6](/filings/0000833640-24-000171.md) | [43.3 d](/filings/0000833640-26-000037.md) | [43.9](/filings/0000833640-25-000120.md) | [49.7](/filings/0000833640-25-000157.md) | [52.7](/filings/0000833640-25-000190.md) | [48.0 d](/filings/0000833640-26-000037.md) | [47.3](/filings/0000833640-26-000078.md) | [51.9](/filings/0000833640-26-000145.md) | [54.1](/filings/0000833640-25-000190.md) | [48.6 d](/filings/0000833640-26-000037.md) | [51.4](/filings/0000833640-26-000078.md) | [54.3](/filings/0000833640-26-000145.md) |
| Gross profit | $m | [65.9](/filings/0000833640-24-000171.md) | [46.2 d](/filings/0000833640-26-000037.md) | [47.8](/filings/0000833640-25-000120.md) | [56.5](/filings/0000833640-25-000157.md) | [63.2](/filings/0000833640-25-000190.md) | [57.3 d](/filings/0000833640-26-000037.md) | [58.2](/filings/0000833640-26-000078.md) | [64.0](/filings/0000833640-26-000145.md) | [64.9](/filings/0000833640-25-000190.md) | [54.6 d](/filings/0000833640-26-000037.md) | [56.9](/filings/0000833640-26-000078.md) | [64.6](/filings/0000833640-26-000145.md) |
| Research and development | $m | [24.1](/filings/0000833640-24-000171.md) | [23.5 d](/filings/0000833640-26-000037.md) | [23.2](/filings/0000833640-25-000120.md) | [26.0](/filings/0000833640-25-000157.md) | [25.8](/filings/0000833640-25-000190.md) | [25.7 d](/filings/0000833640-26-000037.md) | [24.1](/filings/0000833640-26-000078.md) | [26.0](/filings/0000833640-26-000145.md) | [26.7](/filings/0000833640-25-000190.md) | [24.3 d](/filings/0000833640-26-000037.md) | [26.3](/filings/0000833640-26-000078.md) | [27.2](/filings/0000833640-26-000145.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | [27.4](/filings/0000833640-26-000078.md) | [30.2](/filings/0000833640-26-000145.md) | not reported | not reported | [24.4](/filings/0000833640-26-000078.md) | [28.1](/filings/0000833640-26-000145.md) |
| Operating income | $m | [17.7](/filings/0000833640-24-000171.md) | [(1.1) d](/filings/0000833640-26-000037.md) | [0.5](/filings/0000833640-25-000120.md) | [2.0](/filings/0000833640-25-000157.md) | [11.6](/filings/0000833640-25-000190.md) | [3.9 d](/filings/0000833640-26-000037.md) | [6.7](/filings/0000833640-26-000078.md) | [(1.3)](/filings/0000833640-26-000145.md) | [(4.0)](/filings/0000833640-25-000190.md) | [8.8 d](/filings/0000833640-26-000037.md) | [1.5](/filings/0000833640-26-000078.md) | [8.9](/filings/0000833640-26-000145.md) |
| Income tax | $m | [1.1](/filings/0000833640-24-000171.md) | [(12.0) d](/filings/0000833640-26-000037.md) | [0.0](/filings/0000833640-25-000120.md) | [0.3](/filings/0000833640-25-000157.md) | [0.0](/filings/0000833640-25-000190.md) | [(1.8) d](/filings/0000833640-26-000037.md) | [1.1](/filings/0000833640-26-000078.md) | [(0.0)](/filings/0000833640-26-000145.md) | [(0.0)](/filings/0000833640-25-000190.md) | [(2.1) d](/filings/0000833640-26-000037.md) | [0.6](/filings/0000833640-26-000078.md) | [1.4](/filings/0000833640-26-000145.md) |
| Net income | $m | [19.8](/filings/0000833640-24-000171.md) | [14.3 d](/filings/0000833640-26-000037.md) | [4.0](/filings/0000833640-25-000120.md) | [4.8](/filings/0000833640-25-000157.md) | [14.3](/filings/0000833640-25-000190.md) | [9.1 d](/filings/0000833640-26-000037.md) | [8.8](/filings/0000833640-26-000078.md) | [1.4](/filings/0000833640-26-000145.md) | [(1.4)](/filings/0000833640-25-000190.md) | [13.3 d](/filings/0000833640-26-000037.md) | [3.3](/filings/0000833640-26-000078.md) | [9.8](/filings/0000833640-26-000145.md) |
| Diluted EPS | $ per share | [0.34](/filings/0000833640-24-000171.md) | not reported | [0.07](/filings/0000833640-25-000120.md) | [0.09](/filings/0000833640-25-000157.md) | [0.25](/filings/0000833640-25-000190.md) | not reported | [0.15](/filings/0000833640-26-000078.md) | [0.02](/filings/0000833640-26-000145.md) | [(0.02)](/filings/0000833640-25-000190.md) | not reported | [0.06](/filings/0000833640-26-000078.md) | [0.17](/filings/0000833640-26-000145.md) |
| Basic EPS | $ per share | [0.34](/filings/0000833640-24-000171.md) | not reported | [0.07](/filings/0000833640-25-000120.md) | [0.09](/filings/0000833640-25-000157.md) | [0.25](/filings/0000833640-25-000190.md) | not reported | [0.15](/filings/0000833640-26-000078.md) | [0.02](/filings/0000833640-26-000145.md) | [(0.02)](/filings/0000833640-25-000190.md) | not reported | [0.06](/filings/0000833640-26-000078.md) | [0.18](/filings/0000833640-26-000145.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [94.7](/filings/0000833640-23-000193.md) | [63.9](/filings/0000833640-25-000043.md) | [56.4](/filings/0000833640-24-000107.md) | [50.5](/filings/0000833640-24-000147.md) | [58.5](/filings/0000833640-24-000171.md) | [51.0](/filings/0000833640-26-000037.md) | [49.6](/filings/0000833640-25-000120.md) | [66.9](/filings/0000833640-25-000157.md) | [48.6](/filings/0000833640-25-000190.md) | [58.8](/filings/0000833640-26-000145.md) | [63.4](/filings/0000833640-26-000078.md) | [70.6](/filings/0000833640-26-000145.md) |
| Current assets | $m | [556](/filings/0000833640-23-000193.md) | [512](/filings/0000833640-25-000043.md) | [502](/filings/0000833640-24-000107.md) | [500](/filings/0000833640-24-000147.md) | [508](/filings/0000833640-24-000171.md) | [514](/filings/0000833640-26-000037.md) | [500](/filings/0000833640-25-000120.md) | [483](/filings/0000833640-25-000157.md) | [456](/filings/0000833640-25-000190.md) | [458](/filings/0000833640-26-000145.md) | [458](/filings/0000833640-26-000078.md) | [471](/filings/0000833640-26-000145.md) |
| Total assets | $m | [865](/filings/0000833640-23-000193.md) | [820](/filings/0000833640-25-000043.md) | [806](/filings/0000833640-24-000107.md) | [805](/filings/0000833640-24-000147.md) | [825](/filings/0000833640-24-000171.md) | [829](/filings/0000833640-26-000037.md) | [814](/filings/0000833640-25-000120.md) | [798](/filings/0000833640-25-000157.md) | [773](/filings/0000833640-25-000190.md) | [772](/filings/0000833640-26-000145.md) | [771](/filings/0000833640-26-000078.md) | [779](/filings/0000833640-26-000145.md) |
| Current liabilities | $m | [53.4](/filings/0000833640-23-000193.md) | [48.9](/filings/0000833640-25-000043.md) | [49.5](/filings/0000833640-24-000107.md) | [50.2](/filings/0000833640-24-000147.md) | [50.8](/filings/0000833640-24-000171.md) | [55.3](/filings/0000833640-26-000037.md) | [55.0](/filings/0000833640-25-000120.md) | [65.0](/filings/0000833640-25-000157.md) | [71.1](/filings/0000833640-25-000190.md) | [70.4](/filings/0000833640-26-000145.md) | [66.6](/filings/0000833640-26-000078.md) | [66.6](/filings/0000833640-26-000145.md) |
| Total liabilities | $m | [80.4](/filings/0000833640-23-000193.md) | [67.6](/filings/0000833640-25-000043.md) | [67.6](/filings/0000833640-24-000107.md) | [74.0](/filings/0000833640-24-000147.md) | [75.8](/filings/0000833640-24-000171.md) | [79.1](/filings/0000833640-26-000037.md) | [78.6](/filings/0000833640-25-000120.md) | [93.7](/filings/0000833640-25-000157.md) | [101](/filings/0000833640-25-000190.md) | [99.4](/filings/0000833640-26-000145.md) | [98.9](/filings/0000833640-26-000078.md) | [98.5](/filings/0000833640-26-000145.md) |
| Shareholders' equity | $m | [785](/filings/0000833640-24-000171.md) | [752](/filings/0000833640-26-000037.md) | [738](/filings/0000833640-25-000120.md) | [731](/filings/0000833640-25-000157.md) | [749](/filings/0000833640-25-000190.md) | [750](/filings/0000833640-26-000145.md) | [736](/filings/0000833640-26-000145.md) | [704](/filings/0000833640-26-000145.md) | [672](/filings/0000833640-25-000190.md) | [673](/filings/0000833640-26-000145.md) | [672](/filings/0000833640-26-000145.md) | [681](/filings/0000833640-26-000145.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [26.7 d](/filings/0000833640-24-000171.md) | [16.3 d](/filings/0000833640-26-000037.md) | [15.9](/filings/0000833640-25-000120.md) | [17.6 d](/filings/0000833640-25-000157.md) | [32.9 d](/filings/0000833640-25-000190.md) | [14.7 d](/filings/0000833640-26-000037.md) | [26.4](/filings/0000833640-26-000078.md) | [29.1 d](/filings/0000833640-26-000145.md) | [29.9 d](/filings/0000833640-25-000190.md) | [26.2 d](/filings/0000833640-26-000037.md) | [20.0](/filings/0000833640-26-000078.md) | [22.0 d](/filings/0000833640-26-000145.md) |
| Capital expenditure | $m | [7.5 d](/filings/0000833640-24-000171.md) | [6.1 d](/filings/0000833640-26-000037.md) | [4.3](/filings/0000833640-25-000120.md) | [4.2 d](/filings/0000833640-25-000157.md) | [5.7 d](/filings/0000833640-25-000190.md) | [3.0 d](/filings/0000833640-26-000037.md) | [5.7](/filings/0000833640-26-000078.md) | [5.9 d](/filings/0000833640-26-000145.md) | [5.7 d](/filings/0000833640-25-000190.md) | [7.1 d](/filings/0000833640-26-000037.md) | [2.0](/filings/0000833640-26-000078.md) | [4.3 d](/filings/0000833640-26-000145.md) |
| Dividends paid | $m | [10.9](/filings/0000833640-24-000171.md) | [11.3 d](/filings/0000833640-26-000037.md) | [11.4](/filings/0000833640-25-000120.md) | [11.4](/filings/0000833640-25-000157.md) | [11.4](/filings/0000833640-25-000190.md) | [11.9 d](/filings/0000833640-26-000037.md) | [12.0](/filings/0000833640-26-000078.md) | [11.8](/filings/0000833640-26-000145.md) | [11.8](/filings/0000833640-25-000190.md) | [11.6 d](/filings/0000833640-26-000037.md) | [12.0](/filings/0000833640-26-000078.md) | [11.9](/filings/0000833640-26-000145.md) |
| Share repurchases | $m | [1.8 d](/filings/0000833640-24-000171.md) | [47.4 d](/filings/0000833640-26-000037.md) | [14.6](/filings/0000833640-25-000120.md) | [11.3 d](/filings/0000833640-25-000157.md) | [0.0 d](/filings/0000833640-25-000190.md) | [1.9 d](/filings/0000833640-26-000037.md) | [23.1](/filings/0000833640-26-000078.md) | [32.6 d](/filings/0000833640-26-000145.md) | [42.4 d](/filings/0000833640-25-000190.md) | [0.0 d](/filings/0000833640-26-000037.md) | [0.0](/filings/0000833640-26-000078.md) | [0.0 d](/filings/0000833640-26-000145.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [57.6](/filings/0000833640-23-000193.md) | [57.6](/filings/0000833640-24-000107.md) | [57.7](/filings/0000833640-24-000147.md) | [57.7](/filings/0000833640-24-000171.md) | [57.1](/filings/0000833640-25-000120.md) | [57.0](/filings/0000833640-25-000157.md) | [57.0](/filings/0000833640-25-000190.md) | [57.1](/filings/0000833640-26-000078.md) | [56.4](/filings/0000833640-26-000145.md) | [55.8](/filings/0000833640-25-000190.md) | [55.9](/filings/0000833640-26-000078.md) | [56.7](/filings/0000833640-26-000145.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 55,873,298 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0000833640-26-000145.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.